Trial Profile
Study of impact of switching from existing long-acting insulin to insulin degludec, a new long-acting insulin, on glycemic control and frequency of hypoglycemia (Study on inpatients)
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2013
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 05 Dec 2013 New trial record